SLC2A1 and urinary bladder neoplasm: Although the subtype information is not available in this study, the expression levels of SLC2A1 and KRT17 in bladder tumors are moderately correlated with the ‘basal’ markers such as KRT16, KRT6A, KRT6C, KRT5, CDH3, KRT6B, and KRT14, while the expression level of GPRC5A is weakly correlated with the ‘luminal’ markers such as KRT19 and ERBB3 (Supplementary Figure 4, Supplementary Table 7), therefore it may be possible to identify progressive ‘basal’ subtype by urinary EV analysis.